Skip to main content

Haemophilia Patients: Information On Product Contamination

Volume 622: debated on Monday 12 February 2001

The text on this page has been created from Hansard archive content, it may contain typographical errors.

asked Her Majesty's Government:Further to the Written Answer by Lord Hunt of Kings Heath on 29 January on haemophilia patients and vCJD in blood products (

WA 37), what consultations the Department of Health had with the Haemophilia Society, as the national patient group, to help determine what information should be provided to haemophilia patients about the fact

that a blood donor whose plasma was used in haemophilia products had been found to have vCJD; and whether in future the department will consult the Haemophilia Society on the management of such incidents. [HL578]

The Department of Health had discussions with the United Kingdom Haemophilia Centre Doctors Organisation on their strategy for providing information to patients but not directly with the Haemophilia Society. The CJD Incident Panel is currently developing a framework for the management of such incidents. This will be subject to consultation with interested bodies, including the Haernophilia Society.